| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 11 | 2024 | 110 | 2.570 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2024 | 375 | 2.380 |
Why?
|
| Primary Myelofibrosis | 6 | 2024 | 56 | 2.360 |
Why?
|
| Myelodysplastic Syndromes | 9 | 2023 | 346 | 2.090 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 763 | 2.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2017 | 44 | 1.120 |
Why?
|
| MicroRNAs | 8 | 2017 | 534 | 1.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 6 | 2021 | 90 | 1.020 |
Why?
|
| Leukemia, B-Cell | 2 | 2022 | 23 | 0.960 |
Why?
|
| Erythrocytes | 2 | 2020 | 255 | 0.960 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 114 | 0.940 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2021 | 128 | 0.840 |
Why?
|
| Neoplasm Proteins | 12 | 2021 | 532 | 0.840 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2022 | 27 | 0.830 |
Why?
|
| Sarcoma | 1 | 2023 | 215 | 0.780 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2021 | 49 | 0.780 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 329 | 0.780 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2020 | 12 | 0.780 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 878 | 0.770 |
Why?
|
| Down Syndrome | 6 | 2023 | 53 | 0.760 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2023 | 292 | 0.750 |
Why?
|
| Neoplastic Stem Cells | 2 | 2021 | 143 | 0.730 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 7 | 2016 | 72 | 0.730 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 9 | 0.720 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 131 | 0.670 |
Why?
|
| Humans | 82 | 2024 | 86643 | 0.650 |
Why?
|
| Megakaryocytes | 6 | 2019 | 36 | 0.650 |
Why?
|
| RNA Interference | 2 | 2017 | 369 | 0.620 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 249 | 0.620 |
Why?
|
| Nuclear Proteins | 6 | 2024 | 696 | 0.610 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 151 | 0.570 |
Why?
|
| Mutation | 18 | 2024 | 3968 | 0.570 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2003 | 113 | 0.530 |
Why?
|
| Leukemia | 5 | 2022 | 320 | 0.520 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 4 | 2012 | 9 | 0.520 |
Why?
|
| Lymphoma, B-Cell | 3 | 2022 | 103 | 0.510 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.500 |
Why?
|
| Hematology | 2 | 2020 | 29 | 0.490 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 31 | 0.490 |
Why?
|
| Hematopoiesis | 3 | 2018 | 163 | 0.480 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.470 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 93 | 0.470 |
Why?
|
| Lymphoma, T-Cell | 4 | 2022 | 48 | 0.470 |
Why?
|
| Gene Rearrangement | 5 | 2021 | 170 | 0.470 |
Why?
|
| Warts | 1 | 2013 | 11 | 0.450 |
Why?
|
| Bone Marrow | 6 | 2022 | 435 | 0.450 |
Why?
|
| Lymph Nodes | 4 | 2022 | 533 | 0.450 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2016 | 154 | 0.450 |
Why?
|
| Agammaglobulinemia | 1 | 2013 | 20 | 0.450 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.450 |
Why?
|
| Homeodomain Proteins | 6 | 2021 | 536 | 0.440 |
Why?
|
| DNA-Binding Proteins | 7 | 2016 | 1208 | 0.440 |
Why?
|
| Immunophenotyping | 6 | 2021 | 211 | 0.440 |
Why?
|
| Multiple Myeloma | 4 | 2022 | 307 | 0.430 |
Why?
|
| Apoptosis | 14 | 2016 | 1683 | 0.430 |
Why?
|
| Mice | 31 | 2023 | 11352 | 0.430 |
Why?
|
| Neutropenia | 1 | 2013 | 215 | 0.430 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2022 | 107 | 0.420 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2022 | 29 | 0.420 |
Why?
|
| Aminopyridines | 2 | 2023 | 38 | 0.420 |
Why?
|
| Immunohistochemistry | 7 | 2022 | 1753 | 0.410 |
Why?
|
| Triazines | 2 | 2023 | 53 | 0.410 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2010 | 176 | 0.400 |
Why?
|
| Bacterial Infections | 1 | 2013 | 182 | 0.400 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 53 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 2438 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 252 | 0.360 |
Why?
|
| Flavoproteins | 4 | 2003 | 25 | 0.360 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2023 | 127 | 0.350 |
Why?
|
| RNA, Messenger | 5 | 2007 | 1981 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 1197 | 0.350 |
Why?
|
| Down-Regulation | 6 | 2022 | 504 | 0.340 |
Why?
|
| Transcription Factors | 8 | 2023 | 1565 | 0.340 |
Why?
|
| Animals | 37 | 2023 | 26582 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2016 | 645 | 0.320 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2021 | 157 | 0.320 |
Why?
|
| Membrane Proteins | 5 | 2016 | 1196 | 0.310 |
Why?
|
| Repressor Proteins | 3 | 2021 | 403 | 0.300 |
Why?
|
| WT1 Proteins | 1 | 2007 | 19 | 0.300 |
Why?
|
| Signal Transduction | 9 | 2022 | 3241 | 0.290 |
Why?
|
| CD36 Antigens | 1 | 2006 | 13 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 456 | 0.290 |
Why?
|
| GATA1 Transcription Factor | 6 | 2017 | 18 | 0.290 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 265 | 0.280 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 106 | 0.280 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1464 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2016 | 120 | 0.270 |
Why?
|
| Erythropoiesis | 2 | 2023 | 52 | 0.250 |
Why?
|
| Glutathione Transferase | 3 | 2003 | 111 | 0.250 |
Why?
|
| Gene Dosage | 3 | 2018 | 207 | 0.250 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 724 | 0.250 |
Why?
|
| Myelopoiesis | 2 | 2016 | 10 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1376 | 0.240 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2021 | 6 | 0.240 |
Why?
|
| Chromosomes, Mammalian | 2 | 2021 | 36 | 0.240 |
Why?
|
| Aniline Compounds | 1 | 2023 | 55 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2016 | 427 | 0.230 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 75 | 0.230 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2001 | 141 | 0.230 |
Why?
|
| Pyrazines | 1 | 2023 | 92 | 0.230 |
Why?
|
| Isoenzymes | 2 | 2001 | 271 | 0.230 |
Why?
|
| Extracellular Traps | 1 | 2022 | 11 | 0.220 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 592 | 0.220 |
Why?
|
| Calreticulin | 1 | 2022 | 13 | 0.220 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 20 | 0.220 |
Why?
|
| Germ Cells | 1 | 2023 | 126 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2015 | 54 | 0.220 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 193 | 0.220 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.210 |
Why?
|
| Male | 25 | 2022 | 40965 | 0.210 |
Why?
|
| Biomarkers | 3 | 2022 | 1718 | 0.210 |
Why?
|
| Stem Cells | 2 | 2019 | 351 | 0.210 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 39 | 0.210 |
Why?
|
| Retroviridae | 1 | 2022 | 79 | 0.210 |
Why?
|
| Child | 12 | 2018 | 6927 | 0.210 |
Why?
|
| Thrombopoiesis | 2 | 2023 | 4 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 302 | 0.200 |
Why?
|
| Peroxidase | 1 | 2021 | 51 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Heat-Shock Proteins | 4 | 2003 | 179 | 0.200 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 479 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 189 | 0.190 |
Why?
|
| Platelet Function Tests | 1 | 2020 | 11 | 0.190 |
Why?
|
| Colonic Neoplasms | 2 | 2004 | 556 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 64 | 0.190 |
Why?
|
| Carrier Proteins | 1 | 2024 | 673 | 0.190 |
Why?
|
| World Health Organization | 2 | 2012 | 103 | 0.190 |
Why?
|
| Telomerase | 1 | 2020 | 55 | 0.190 |
Why?
|
| Aurora Kinase A | 2 | 2019 | 9 | 0.180 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1384 | 0.180 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 51 | 0.180 |
Why?
|
| Thrombosis | 1 | 2022 | 296 | 0.180 |
Why?
|
| Middle Aged | 13 | 2022 | 25028 | 0.180 |
Why?
|
| Cell Lineage | 5 | 2023 | 273 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 3092 | 0.180 |
Why?
|
| Female | 22 | 2022 | 44532 | 0.180 |
Why?
|
| DNA Repair | 1 | 2021 | 356 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 42 | 0.170 |
Why?
|
| Gene Expression | 5 | 2008 | 1284 | 0.170 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 65 | 0.170 |
Why?
|
| Macrophages | 4 | 2010 | 554 | 0.170 |
Why?
|
| Adult | 15 | 2024 | 25648 | 0.170 |
Why?
|
| Cell Nucleus | 3 | 2014 | 579 | 0.160 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 14 | 0.160 |
Why?
|
| Genes, abl | 1 | 1998 | 12 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2021 | 329 | 0.160 |
Why?
|
| Child, Preschool | 8 | 2017 | 3612 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1920 | 0.160 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 71 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2007 | 1004 | 0.160 |
Why?
|
| Neoplasms | 3 | 2022 | 2898 | 0.160 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 55 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 589 | 0.150 |
Why?
|
| Cell Proliferation | 7 | 2018 | 1578 | 0.150 |
Why?
|
| Prognosis | 5 | 2022 | 3679 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 100 | 0.150 |
Why?
|
| Flow Cytometry | 5 | 2016 | 679 | 0.150 |
Why?
|
| Immunoblotting | 4 | 2013 | 268 | 0.150 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 162 | 0.150 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 41 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 84 | 0.140 |
Why?
|
| Cell Differentiation | 6 | 2015 | 1458 | 0.140 |
Why?
|
| Adolescent | 10 | 2024 | 8981 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2017 | 272 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 138 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2016 | 38 | 0.140 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 387 | 0.130 |
Why?
|
| Adenoma | 1 | 2017 | 235 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 3 | 2005 | 305 | 0.130 |
Why?
|
| Granzymes | 1 | 2015 | 93 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 177 | 0.130 |
Why?
|
| Inflammation | 1 | 2020 | 920 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 740 | 0.130 |
Why?
|
| Chromosomal Instability | 1 | 2014 | 19 | 0.130 |
Why?
|
| F-Box Proteins | 1 | 2014 | 8 | 0.130 |
Why?
|
| Cyclin E | 1 | 2014 | 27 | 0.120 |
Why?
|
| Transfection | 6 | 2016 | 896 | 0.120 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 15 | 0.120 |
Why?
|
| Cell Line | 4 | 2016 | 2468 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 272 | 0.120 |
Why?
|
| Genes, myc | 1 | 2014 | 39 | 0.120 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 2232 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 927 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 225 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2014 | 83 | 0.120 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 4 | 2016 | 20 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 124 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2017 | 374 | 0.120 |
Why?
|
| Granulocytes | 2 | 2010 | 37 | 0.120 |
Why?
|
| Infant | 5 | 2017 | 3046 | 0.120 |
Why?
|
| Doxorubicin | 4 | 2007 | 295 | 0.120 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 1204 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 267 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2013 | 19 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 425 | 0.110 |
Why?
|
| Biopsy | 2 | 2014 | 1163 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 165 | 0.110 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 21 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2024 | 8489 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 439 | 0.110 |
Why?
|
| Vincristine | 3 | 2007 | 111 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 44 | 0.110 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2426 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2010 | 33 | 0.110 |
Why?
|
| Aged | 10 | 2021 | 18415 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2017 | 629 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2016 | 712 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 379 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 728 | 0.110 |
Why?
|
| Lymphocytes | 2 | 2008 | 464 | 0.110 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 299 | 0.100 |
Why?
|
| Syndrome | 1 | 2013 | 446 | 0.100 |
Why?
|
| DNA, Complementary | 2 | 2003 | 393 | 0.100 |
Why?
|
| Janus Kinase 2 | 3 | 2019 | 57 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 73 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 322 | 0.100 |
Why?
|
| Young Adult | 6 | 2024 | 5976 | 0.100 |
Why?
|
| India | 4 | 2001 | 120 | 0.100 |
Why?
|
| Phenotype | 3 | 2022 | 2378 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 329 | 0.100 |
Why?
|
| Apoptosis Inducing Factor | 4 | 2003 | 6 | 0.100 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 79 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 879 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 373 | 0.100 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2010 | 13 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 253 | 0.100 |
Why?
|
| Base Sequence | 4 | 2016 | 2330 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 246 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 1195 | 0.090 |
Why?
|
| Molecular Chaperones | 4 | 2003 | 111 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7993 | 0.090 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 5 | 0.090 |
Why?
|
| Fibrosis | 2 | 2022 | 203 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2001 | 18 | 0.090 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 22 | 0.090 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2001 | 27 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 326 | 0.090 |
Why?
|
| Mice, Knockout | 5 | 2015 | 1924 | 0.090 |
Why?
|
| Dura Mater | 1 | 2010 | 44 | 0.090 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 3 | 2003 | 4 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 61 | 0.090 |
Why?
|
| Mitochondria | 2 | 2003 | 535 | 0.090 |
Why?
|
| Herpesviridae | 1 | 2009 | 14 | 0.090 |
Why?
|
| Herpesvirus 8, Human | 1 | 2009 | 11 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2015 | 782 | 0.090 |
Why?
|
| Autografts | 2 | 2020 | 28 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 1014 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 2 | 2007 | 40 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1540 | 0.090 |
Why?
|
| Disease Progression | 3 | 2022 | 1531 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 2008 | 27 | 0.080 |
Why?
|
| Mutant Proteins | 2 | 2022 | 94 | 0.080 |
Why?
|
| Cell Survival | 4 | 2016 | 969 | 0.080 |
Why?
|
| Gene Deletion | 2 | 2015 | 329 | 0.080 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 19 | 0.080 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 16 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 50 | 0.080 |
Why?
|
| Sacrum | 1 | 2008 | 40 | 0.080 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 186 | 0.080 |
Why?
|
| Homeostasis | 1 | 2010 | 409 | 0.080 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 48 | 0.080 |
Why?
|
| Proto-Oncogenes | 2 | 2013 | 61 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1135 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2360 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2271 | 0.080 |
Why?
|
| Trisomy | 1 | 2007 | 55 | 0.080 |
Why?
|
| Protein Binding | 2 | 2019 | 1456 | 0.080 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 148 | 0.080 |
Why?
|
| Prednisolone | 1 | 2007 | 41 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 286 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1939 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 165 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 78 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2003 | 108 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 59 | 0.070 |
Why?
|
| Rituximab | 1 | 2007 | 116 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2019 | 1106 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 235 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 144 | 0.070 |
Why?
|
| Genomics | 2 | 2022 | 720 | 0.070 |
Why?
|
| Spleen | 3 | 2013 | 430 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2818 | 0.070 |
Why?
|
| Cytosol | 2 | 2003 | 189 | 0.070 |
Why?
|
| Mutagenesis | 2 | 2003 | 199 | 0.070 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 153 | 0.070 |
Why?
|
| Lung | 2 | 2022 | 1170 | 0.070 |
Why?
|
| Age Factors | 2 | 2001 | 1851 | 0.060 |
Why?
|
| Remission Induction | 2 | 2012 | 722 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 736 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1998 | 261 | 0.060 |
Why?
|
| Cytochrome c Group | 2 | 2003 | 82 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 27 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 2 | 2016 | 68 | 0.060 |
Why?
|
| Acute Disease | 3 | 2016 | 826 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 646 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 930 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 758 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 2 | 2001 | 20 | 0.060 |
Why?
|
| Rats | 4 | 2004 | 3990 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 93 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 576 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 53 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 64 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2012 | 926 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 100 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 1041 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 100 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 87 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 307 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.060 |
Why?
|
| Interleukin-13 | 1 | 2022 | 36 | 0.060 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2003 | 281 | 0.060 |
Why?
|
| Curriculum | 1 | 2007 | 539 | 0.060 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 38 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 107 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 51 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 270 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 127 | 0.050 |
Why?
|
| Abnormal Karyotype | 1 | 2022 | 8 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 5210 | 0.050 |
Why?
|
| Karyotype | 1 | 2022 | 33 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 526 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 425 | 0.050 |
Why?
|
| Protein Transport | 1 | 2003 | 411 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2001 | 51 | 0.050 |
Why?
|
| Transcriptome | 2 | 2016 | 580 | 0.050 |
Why?
|
| Models, Biological | 4 | 2019 | 1749 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2062 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6509 | 0.050 |
Why?
|
| Symbiosis | 1 | 2022 | 118 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2022 | 92 | 0.050 |
Why?
|
| Plasmids | 1 | 2001 | 287 | 0.050 |
Why?
|
| Autopsy | 1 | 2021 | 116 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 16 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 20 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 195 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 639 | 0.050 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2000 | 37 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 50 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2013 | 4213 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 1074 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 674 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2001 | 170 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 996 | 0.050 |
Why?
|
| Cell Division | 1 | 2001 | 696 | 0.050 |
Why?
|
| Peptides | 1 | 2003 | 639 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 269 | 0.050 |
Why?
|
| Telomere | 1 | 2020 | 108 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 223 | 0.040 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2019 | 13 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 348 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 179 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2261 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 447 | 0.040 |
Why?
|
| Genes, MDR | 1 | 1998 | 7 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2001 | 729 | 0.040 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2008 | 15 | 0.040 |
Why?
|
| Caspases | 3 | 2003 | 155 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1998 | 220 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2018 | 94 | 0.040 |
Why?
|
| Hepatitis B | 1 | 1998 | 74 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 1156 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 236 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2017 | 80 | 0.040 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2016 | 18 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2012 | 628 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 20 | 0.040 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.040 |
Why?
|
| Anemia | 1 | 2018 | 128 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 43 | 0.040 |
Why?
|
| DNA | 1 | 2022 | 1294 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2007 | 83 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.040 |
Why?
|
| Tretinoin | 1 | 2016 | 126 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 229 | 0.040 |
Why?
|
| Prednisone | 2 | 2007 | 258 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2007 | 293 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Polyploidy | 1 | 2015 | 17 | 0.030 |
Why?
|
| Azepines | 1 | 2015 | 20 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 251 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 777 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 92 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1998 | 208 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 85 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 37 | 0.030 |
Why?
|
| Nitriles | 1 | 2015 | 149 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 158 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 420 | 0.030 |
Why?
|
| Integrases | 1 | 2015 | 59 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 303 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 217 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 150 | 0.030 |
Why?
|
| Sex Factors | 1 | 1998 | 1054 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 157 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 180 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2007 | 329 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 365 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 214 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2015 | 153 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 99 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1961 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2014 | 109 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 615 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 100 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 26 | 0.030 |
Why?
|
| Chromatin | 2 | 2009 | 380 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 96 | 0.030 |
Why?
|
| Etoposide | 2 | 2004 | 196 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 179 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 339 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 133 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 63 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1098 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 104 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 37 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 103 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2015 | 370 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 127 | 0.030 |
Why?
|
| Thrombocytosis | 1 | 2012 | 8 | 0.030 |
Why?
|
| U937 Cells | 2 | 2003 | 32 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 112 | 0.030 |
Why?
|
| Calcineurin | 1 | 2012 | 16 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2003 | 33 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 966 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2012 | 68 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1565 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 236 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 218 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1863 | 0.020 |
Why?
|
| United States | 1 | 2024 | 6672 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 689 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 183 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 2009 | 14 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2009 | 14 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 860 | 0.020 |
Why?
|
| Genotype | 2 | 2007 | 1851 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1047 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1686 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1805 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1230 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3030 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 52 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 59 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 229 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 937 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 813 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 450 | 0.020 |
Why?
|
| Incidence | 2 | 2001 | 1577 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2004 | 15 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2004 | 49 | 0.020 |
Why?
|
| Staurosporine | 1 | 2004 | 33 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2003 | 26 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2003 | 48 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2004 | 151 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 41 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 103 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 159 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 71 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1621 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 100 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2003 | 93 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 268 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2357 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 256 | 0.010 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Chaperonin 60 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 20 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2001 | 82 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 439 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2001 | 46 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 612 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 83 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2001 | 46 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 881 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 123 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 286 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 444 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2000 | 148 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2001 | 227 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 444 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1286 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2003 | 1078 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 692 | 0.010 |
Why?
|
| Research | 1 | 2000 | 253 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 2379 | 0.010 |
Why?
|